MOHW FDA No. 11131102726 Announcement dated May 24, 2024

Notices for the Plant Master File (PMF) Application **Form C-1**

Plant Master File (PMF) Checklist for Foreign Pharmaceutical Manufacturer

Form C-1: Documents in Common review (For the expansion of manufacturing site, the items which are marked with asterisk are required, and the relevant documents shall be enclosed.)

Applicant:	**Receipt No.**	**Case Number**
Item	Please complete the Checklist item by item and indicate the attachment numbers or the page numbers of **submitted documents**	Reviewer's comment
*1.1 Name of manufacturer (which shall be consistent with that shown in the official supporting documents)		
*1.2 Address of manufacturer (which shall be exact detailed and consistent with that shown in the official supporting documents; and give both contact address and site address, if different)		
1.3 Legalization requirements: Based on Article 5, Paragraph 2 of the "Regulations of Medicament Manufacturer Inspection, the PMF application dossier for submission shall meet one of the following requirements for submission: ☐ PMF or SMF, which is to be certified by the highest competent health authority or the chamber of commerce in the country of origin or legalized by the embassy, representative office or agencies authorized by the Ministry of Foreign Affairs of R.O.C. ☐ Original copy of documents from the hosting competent authority or certified photocopy of the said documents certified by the hosting competent authority or chamber of commerce in the country of origin proving that the manufacturer is in compliance with local pharmaceutical GMP standards. (if the two original documents mentioned above were already submitted to the TFDA through other cases, a photocopy of the whole document may be enclosed and indication of the case number that the original copies were submitted.) ☐ Original copy of Certificate of Pharmaceutical Product (CPP) from the hosting competent authority or certified		

photocopy of the said documents certified by the by the hosting competent authority or chamber of commerce in the country of origin clearly stating that said manufacturer is in compliance with local pharmaceutical GMP standards. (if the two original documents mentioned above were already submitted to the TFDA through other cases, a photocopy of the whole document may be enclosed and indication of the case number that the original copies were submitted.) ☐ If the paper based GMP certification is no longer available in the country of origin, or the drug product is contracted manufacturing, the statement of license holder of the imported drug shall be submitted explaining why the GMP certification and CPP is not available. Therefore, the applicants could submit the original copy or certified photocopy of the CPP issued by any one of the A-10 countries, EMA, or by the highest competent health authority in the country where the contractor is located, in accordance with the letter TFDA Risk No. 1051105400 dated October 17, 2016.		
*1.4 Dosage form/product/manufacturing process applied in the application 1.4.1 Completed by the Taiwan pharmaceutical company, with indication of the manufacturing process stage being applied for.		
For ATMPs/biological medicinal products, and Products derives from human plasma, the product/dosage form and manufacturing process stage shall be specified, and the following items shall be checked: ☐ Animal sourced products ☐ Allergen products ☐ Animal immunosera products ☐ Vaccines ☐ Recombinant products ☐ Monoclonal antibody products ☐ Transgenic animal products ☐ Transgenic plant products ☐ Gene therapy products ☐ Somatic and xenogeneic cell therapy products and tissue engineered products ☐ Blood products		
*1.4.2 Explain if special products (biological medicinal products, highly sensitizing, highly pharmacological active, toxic, or hazardous substances) are included **in the Dosage form/product/manufacturing process applied in the application**, such as β-lactam antibiotics (e.g., penicillin, cephalosporins, Penems, Carbacephem, Monobactams), Hormone (include sex		

hormones and non-sex hormones), cytotoxics/cytostatic, or radioactive medicinal products.		
*1.4.3Explain whether the manufacturing and testing of **the Dosage form/product/manufacturing process applied in the application** is **full-manufacturing process** or **phased**. **If the production is phased or testing is outsourced, the implementation stage in the manufacturing site shall be specified separately.**		
For applicants applying for simplified review for non-sterile dosage form except for secondary packaging, the flowchart of major manufacturing steps for the applied dosage form/manufacturing process are required.		
*1.4.4 Enclose the layout of production area (from weighing to secondary packaging and shall include personnel/material flow, air flow/pressure difference and room cleanness) and address the area for the Dosage form/product/manufacturing process applied in the application.		
1.5 The approval letter holds by applicant or other pharmaceutical companies. ☐The TFDA issued approval letter holds by applicant already, photocopies enclosed. ☐When applying for quote review: The TFDA-issued approval letter holds by applicant or other companies, photocopies enclosed.		
1.6 Overview of the manufacturing site		
1.6.1Briefly describe the premises (area, location, surroundings)		
*1.6.2Site layout, with indication of purposes of respective buildings and each floor in the site. Address the buildings and floors for the Dosage form/product/manufacturing process applied in the application.		
1.6.3 Describe the outsourced activities and the contracts.		
1.7 Manufacturing activity at the site approved by the competent authority in the original country (**photocopy of the official document**)		
1.8 **Description of the all production activity in the site**		
*1.8.1 List the products currently manufactured (including manufacturing and packaging) at the manufacturing site according to dosage forms. Specify the category, active ingredient, and production area for each product. Categories should include human medicinal products, human investigational medicinal products, veterinary medicinal products, medical devices,		

cosmetic products, food, herbal products, or others. If any product falls under the categories listed in item 1.8.2.1, indicate its special product category in the list. If the list provided by the manufacturer is not listed by dosage forms, the Taiwan pharmaceutical company shall organize and list them according to dosage forms.		
*1.8.2 Are specific products manufactured in the site? (If yes, go on to complete 1.8.2.1—1.8.2.3.)	Y/N	
*1.8.2.1 Mark the appropriate boxes in this table below corresponding to the special product categories manufactured onsite (mark 'x' if **not** manufactured), and specify the dosage form of each product. If this table is completed by the Taiwan pharmaceutical company, a manufacturer's statement of clarification shall be attached. ☐Penicillins ☐Cephalosporins ☐Penems ☐Carbacephem ☐Monobactams ☐Estrogen ☐Sex hormones ☐General hormone (include steroids) ☐Substances with hormone activity ☐Cytotoxic ☐Cytostatic ☐Biological medicinal products ☐Radioactive medicinal products ☐Others ( )		
*1.8.2.2 If specific products indicated in 1.8.2.1 are manufactured, please specify the measure of production of these products, such manufacturing premises/facilities/equipment design (segregated premises, segregated production areas, dedicated equipment in the shared production areas or shared facilities and equipment with non-specific medicinal products, etc.) and **indicate production areas for said products in the layout.**		
*1.8.2.3 For dedicated equipment in the shared production areas or shared facilities and equipment with non-specific medicinal products, please provide the following documents: A. A description letter or assessment report of measures to prevent cross-contamination based on the Quality Risk Management process (including potency and toxicological evaluation such as Health Based Exposure Limit (HBEL)-PDE/ADE). Factors shall be included but not be limited to the design and use of facility/equipment, personnel and material flow, physico-chemical characteristics of the active ingredients, process characteristics, and cleaning processes. B. Periodic reviews of the effectiveness of measures to prevent cross-contamination.		

C. A summary of cleaning validation, which shall include, but not be limited to, the method of executing cleaning validation. If conducted in a group manner, describe the grouping criteria, list the active ingredients of products within each group, and identify the representative product for the cleaning validation.		
*1.8.3 Are other non-human medicinal products (such as veterinary medicinal products), medical devices, cosmetics, foods, herbal medicine, homeopathic products or other products also manufactured in the site? (If yes, go on to complete 1.8.3.1—1.8.3.2.2.)	Y/N	
*1.8.3.1Please mark the appropriate boxes in this table below corresponding to those products manufactured onsite (mark 'x' if **not** manufactured), and **specify the type of product, dosage form, the composition, and whether the ingredients are usable in the human body, and enclose supporting materials**. If this table is completed by the Taiwan pharmaceutical company, a manufacturer's statement of clarification shall be attached. ☐Veterinary medicinal products (☐can be used in human body ☐can't be used in human body) ☐Foods ☐Cosmetics ☐Medical devices (☐ Ingredients is included in pharmacopoeia ☐Ingredients is not included in pharmacopoeia) ☐Herbal medicine ☐Homeopathic products ☐Other products ☐Feed		
*1.8.3.2If the certain products indicated in 1.8.3 are manufactured, please specify the measure of production of these products, such manufacturing premises/facilities/equipment design (segregated premises, segregated production areas, dedicated equipment in the shared production areas or shared facilities and equipment with human medicinal products, etc.) and **indicate production areas for said products in the layout.**		
*1.8.3.2.1 For dedicated equipment in the shared production areas with human medicinal products, the following shall be described: A. Is the active ingredient of certain products archived in the pharmacopoeia? If yes, enclose relevant bases. B. Is the manufacturing in compliance with the PIC/S GMP standards? (The statement shall be written		

and signed by the manufacturer) C. A description letter or assessment report of measures to prevent cross-contamination based on the Quality Risk Management process (including the design and use of facility/equipment, personnel and material flow, microbial controls, list of raw materials, physico-chemical characteristics of the active ingredients, process characteristics, and cleaning processes.) Periodic reviews of the effectiveness of measures to prevent cross-contamination.		
*1.8.3.2.2 For shared facilities and equipment with human medicinal products, the following shall be described in detail: A. Is the active ingredient of certain products archived in the pharmacopoeia? If yes, enclose relevant bases. B. A statement letter or assessment report of measures to prevent cross-contamination based on the Quality Risk Management process (including the design and use of facility/equipment, personnel and material flow, microbial controls, list of raw materials, physico-chemical characteristics of the active ingredients, process characteristics, and cleaning processes.) Periodic reviews of the effectiveness of measures to prevent cross-contamination. C. If the veterinary medicinal products and human medicinal products are manufactured at the same facilities and share same equipment, and the said veterinary medicinal products are not used in Human, the following dossiers shall be submitted: the risk assessment report including toxicological data, Health Based Exposure Limit (HBEL)PDE /ADE , and correspondence measurements to prevent from cross contamination. (If the veterinary medicinal products are not manufactured from weighing to primary packaging at the same facility which also produce human medicinal products, this item is not required.) D. If the veterinary medicinal products and human medicinal products are manufactured at the same facilities and share same equipment, list shared equipments, specify the dosage form and composition, and attached a summary of cleaning validation (include the method of executing cleaning validation. If conducted in a group manner, describe the grouping criteria, list the		

	active ingredients of products within each group, and identify the representative product for the cleaning validation.) (If the veterinary medicinal products are not manufactured from weighing to primary packaging at the same facility which also produce human medicinal products, this item is not required.)		
		Signature (including date of signing)	